Theriva announces orphan medicinal product designation by EMA to VCN-01
PremiumThe FlyTheriva announces orphan medicinal product designation by EMA to VCN-01
28d ago
Theriva Biologics’ SYN-004 receives positive DSMC review in Phase 1/2 trial
Premium
The Fly
Theriva Biologics’ SYN-004 receives positive DSMC review in Phase 1/2 trial
1M ago
Theriva Biologics Advances SYN-004 in Clinical Trial
Premium
Company Announcements
Theriva Biologics Advances SYN-004 in Clinical Trial
1M ago
Theriva Biologics achieves target patient enrollment in VIRAGE Phase 2b trial
PremiumThe FlyTheriva Biologics achieves target patient enrollment in VIRAGE Phase 2b trial
2M ago
Theriva Biologics Secures Funding for Viral Therapy Innovation
Premium
Company Announcements
Theriva Biologics Secures Funding for Viral Therapy Innovation
2M ago
Theriva Biologics awarded manufacturing funding from Spanish government
Premium
The Fly
Theriva Biologics awarded manufacturing funding from Spanish government
2M ago
Theriva Biologics reports Q2 EPS (43c), consensus (70c)
PremiumThe FlyTheriva Biologics reports Q2 EPS (43c), consensus (70c)
3M ago
Theriva Biologics Gains FDA Nod and Converts Preferred Stock
Premium
Company Announcements
Theriva Biologics Gains FDA Nod and Converts Preferred Stock
3M ago
Theriva Biologics announces FDA granted RPPD for VCN-01
Premium
The Fly
Theriva Biologics announces FDA granted RPPD for VCN-01
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100